Enliven Therapeutics (ELVN) EBIT (2019 - 2026)

Enliven Therapeutics has disclosed EBIT across 8 years of filings, most recently posting -$27.8 million for Q1 2026.

• EBIT for Q1 2026 came in at -$27.8 million, up 12.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.9 million (up 83.76% YoY), and the FY2025 annual result was -$21.8 million, up 79.17% from the prior year.
• EBIT came in at -$27.8 million for Q1 2026 at Enliven Therapeutics, down from $63.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $63.6 million in Q4 2025 to a low of -$31.7 million in Q1 2025.
• The 5-year median for EBIT is -$24.2 million (2023), against an average of -$16.3 million.
• Across the five-year window, EBIT tumbled 123.64% in 2023 and jumped 336.46% in 2025, its largest moves.
• Enliven Therapeutics' EBIT stood at -$10.2 million in 2022, then tumbled by 123.64% to -$22.7 million in 2023, then dropped by 18.33% to -$26.9 million in 2024, then soared by 336.46% to $63.6 million in 2025, then sank by 143.75% to -$27.8 million in 2026.
• The last three EBIT figures came in at -$27.8 million (Q1 2026), $63.6 million (Q4 2025), and -$25.1 million (Q3 2025), per Business Quant data.